Immunoprotection by a Nucleic Acid Vaccine from the GRA1 Gene of Toxoplasma Gondii

LIU Hui-ying,SUN Ling,LI Shu-hong,GONG Peng-tao,LI Jian-hua,ZHANG Xi-chen

DOI: https://doi.org/10.13350/j.cjpb.2012.03.012

2012-01-01

Abstract:Objective To construct a recombinant eukaryotic expression plasmid containing the dense granule protein 1(GRA1) gene of Toxoplasma gondii and to express this gene in Hela cells and study its immunological protection.Methods T.gondii total RNA was used as a template to design a pair of primers to amplify cDNA fragments of GRA1.The recombinant eukaryotic expression plasmid pVAX1-GRA1 was constructed and transfected into Hela cells to test its expression in cells.Its protective effect was evaluated based on the serum levels of IgG and percentage of CD4 and CD8 cells.The survival time of vaccinated mice challenged with T.gondii was observed.Results PCR amplification produced an open reading frame of GRA1 of about 573 bp and the recombinant expression plasmid pVAX1-GRA1 was constructed.Specific protein in Hela cells transfected with pVAX1-GRA1 was detected.The protein was found to have a certain degree of immunogenicity.Results indicated that the DNA vaccine provided protection,increasing the antibody titer and significantly increasing(P0.01) the percentage of CD4+ and CD8+ lymphocytes compared to the control group.The results of SDS-PAGE revealed that the molecular weight of the recombinant protein was 24 ku.Mice immunized with the vaccine had an increased survival time(165±23.1)d compared to control mice given PBS.The pVAX1 control group died within(144±16.3)d and(148±16.3)d of the challenge,and the difference in survival time was statistically significant(P0.05).Conclusion A nucleic acid vaccine containing pVAX1-GRA1 can provide partial immunoprotection and is a promising candidate for use in future studies of vaccination against T.gondii.